Bosh sahifaALKS • NASDAQ
add
Alkermes Plc
Yopilish kursi
28,42 $
Kunlik diapazon
27,90 $ - 28,46 $
Yillik diapazon
22,90 $ - 32,88 $
Bozor kapitalizatsiyasi
4,54 mlrd USD
Oʻrtacha hajm
1,51 mln
Narx/foyda
14,32
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 378,14 mln | -0,73% |
Joriy xarajat | 210,29 mln | -8,67% |
Sof foyda | 92,38 mln | 93,44% |
Sof foyda marjasi | 24,43 | 94,82% |
Har bir ulushga tushum | 0,73 | 14,06% |
EBITDA | 111,73 mln | 3,59% |
Amaldagi soliq stavkasi | 15,82% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 908,86 mln | 2,22% |
Jami aktivlari | 2,16 mlrd | -5,44% |
Jami passivlari | 863,18 mln | -6,55% |
Umumiy kapital | 1,29 mlrd | — |
Tarqatilgan aksiyalar | 161,80 mln | — |
Narxi/balansdagi bahosi | 3,56 | — |
Aktivlardan daromad | 12,01% | — |
Kapitaldan daromad | 15,82% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 92,38 mln | 93,44% |
Operatsiyalardan naqd pul | 81,59 mln | -18,17% |
Sarmoyadan naqd pul | -109,33 mln | 8,40% |
Moliyadan naqd pul | -111,11 mln | -7 190,87% |
Naqd pulning sof oʻzgarishi | -138,86 mln | -667,84% |
Boʻsh pul | 31,74 mln | -63,37% |
Haqida
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Tashkil etilgan
1987
Sayt
Xodimlar soni
2 100
